SAVVY Vaginal Gel (C31G) for Prevention of HIV Infection: A Randomized Controlled Trial in Nigeria
PLoS ONEPublished 22 January 2008Open access
Paul J. Feldblum, Adesina Adeiga, R A Bakare, Silver Wevill, Anja Lendvay, Fatimah Obadaki
Citations282
SJR quartileQ1
SJR score0.80
SNIP1.07
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Although the hazard ratio was higher in the SAVVY than the placebo group, it cannot conclude that there was a harmful treatment effect of S AVVY, which did not reduce the incidence of HIV infection.
Abstract
SAVVY did not reduce the incidence of HIV infection. Although the hazard ratio was higher in the SAVVY than the placebo group, we cannot conclude that there was a harmful treatment effect of SAVVY.
Keywords
Immunology and MicrobiologyMedicine
Springer series in statisticsNonparametric Estimation from Incomplete Observations
45,533 Citations1992Edward L. Kaplan, Paul Meier
Journal of the American Statistical AssociationNonparametric Estimation from Incomplete Observations
39,052 Citations1958Edward L. Kaplan, Paul Meier
The LancetThe CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials
5,372 Citations2001David Moher, Kenneth F. Schulz +1 more
The revised CONSORT statement presented here incorporates new evidence and addresses some criticisms of the original statement to improve the reporting of an RCT, enabling readers to understand a trial's conduct and to assess the validity of its results.
BiometricsA Multiple Testing Procedure for Clinical Trials
3,349 Citations1979Peter C. O’Brien, Thomas R. Fleming
The overall size of the procedure is shown to be controlled with virtually the same accuracy as the single sample chi-square test based on N(m1 + m2) observations and the power is found to bevirtually the same.
BMC Medical Research MethodologyThe CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials
2,754 Citations2001David Moher, Kenneth F. Schulz +1 more
The revised CONSORT statement is intended to improve the reporting of an RCT, enabling readers to understand a trial's conduct and to assess the validity of its results.
BiometrikaDiscrete sequential boundaries for clinical trials
1,740 Citations1983K. K. Gordon Lan, David L. DeMets
A more flexible way to construct discrete sequential boundaries is proposed, based on the choice of a function, a*(t), which characterizes the rate at which the error level ac is spent.
The LancetEffectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial
795 Citations2002Lut Van Damme, Gita Ramjee +12 more
This study did not show a protective effect of COL-1492 on HIV-1 transmission in high-risk women, and this drug can no longer be deemed a potential HIV- 1-prevention method.
JAMAEfficacy of Nonoxynol 9 Contraceptive Sponge Use in Preventing Heterosexual Acquisition of HIV in Nairobi Prostitutes
392 Citations1992Joan K. Kreiss
It was unable to demonstrate that nonoxynol 9 sponge use was effective in reducing the risk of HIV infection among highly exposed women.
New England Journal of MedicineA Controlled Trial of Nonoxynol 9 Film to Reduce Male-to-Female Transmission of Sexually Transmitted Diseases
368 Citations1998Ronald E. Roddy, Léopold Zekeng +4 more
PLoS Clinical TrialsTenofovir Disoproxil Fumarate for Prevention of HIV Infection in Women: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial
276 Citations2007Leigh Peterson, Doug Taylor +10 more
Daily oral use of TDF in HIV-uninfected women was not associated with increased clinical or laboratory adverse events and effectiveness could not be conclusively evaluated because of the small number of HIV infections observed during the study.
American Journal of EpidemiologyEvidence of a Healthy Volunteer Effect in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
229 Citations2007Paul F. Pinsky, Anthony B. Miller +9 more
The authors compared demographics, mortality rates, and cancer incidence and survival rates of PLCO subjects during the early phase of the trial with those of the US population.
PLoS ONESAVVY® (C31G) Gel for Prevention of HIV infection in Women: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial in Ghana
190 Citations2007Leigh Peterson, Kavita Nanda +9 more
SAVVY was not associated with increased adverse events overall, but was associated with higher reporting of reproductive adverse events, and it is insufficient to conclude whether SAVVY is effective at preventing HIV infection relative to placebo.
The LancetMicrobicide drug candidates to prevent HIV infection
184 Citations2007Jan Balzarini, Lut Van Damme
Different categories of microbicide drugs and lead compounds, their mechanism of action, current status of development, and progress in phase III trials are reviewed.
The Lancet Infectious DiseasesNonoxynol-9 spermicide for prevention of vaginally acquired HIV and other sexually transmitted infections: systematic review and meta-analysis of randomised controlled trials including more than 5000 women
109 Citations2002David Wilkinson, Maya Tholandi +2 more
No statistically significant reduction in risk of HIV and STIs is found, and the confidence intervals indicate that any protection that may exist is likely to be very small, and N-9 cannot be recommended for HIV andSTI prevention.
Antimicrobial Agents and ChemotherapySodium Dodecyl Sulfate and C31G as Microbicidal Alternatives to Nonoxynol 9: Comparative Sensitivity of Primary Human Vaginal Keratinocytes
79 Citations2000Fred C. Krebs, Shendra R. Miller +5 more
Results reveal important variations in time- and concentration-dependent sensitivity to N-9, C31G, or SDS within populations of primary human vaginal keratinocytes cultured in vitro.
PubMedHeterosexual HIV transmission.
74 Citations1995Mayer Kh, Deverick J. Anderson
Control of the heterosexual HIV epidemic will necessitate a multidisciplinary approach, utilizing direct biological approaches (e.g., culturally specific and behavioral interventions) as well as more fundamental community changes that decrease societal norms that augment unsafe practices.
PubMedHeterosexual transmission of human immunodeficiency virus type 1 from transfusion recipients to their sex partners.
67 Citations1994T R O'Brien, Michael P. Busch +8 more
The data suggest that HIV-1-infected men who develop immunodeficiency rapidly are more likely to infect their sex partners and that the greater efficiency of male-to-female HIV- 1 transmission is not explained by a greater number of sexual contacts or more advanced immunodficiency in index subjects.
ContraceptionFourteen-day safety and acceptability study of the universal placebo gel
64 Citations2006Jill L. Schwartz, Susan A. Ballagh +5 more
The universal placebo was associated with few and mild genital symptoms, few and minor colposcopic findings and good vaginal health with no clinically significant changes in genital flora and the strategy of creating a de novo inert universal placebo is a successful approach.
New England Journal of MedicineCondoms and Sexually-Transmitted Infections
57 Citations2006M. Steiner, Willard Cates
There is strong evidence that condom use reduces the risk of transmission of HIV, gonorrhea and chlamydia, and herpes simplex virus in both women and men, as well as therisk of HPV infection in women.
The Journal of UrologyA Controlled Trial of Nonoxynol 9 Film to Reduce Male-to-Female Transmission of Sexually Transmitted Diseases
52 Citations1999Ronald E. Roddy, Léopold Zekeng +4 more
The use of a nonoxynol 9 vaginal film did not reduce the rate of new HIV, gonorrhea, or chlamydia infection in this group of sex workers who used condoms and received treatment for sexually transmitted diseases.
ContraceptionA randomized Phase I vaginal safety study of three concentrations of C31G vs. Extra Strength Gynol II
48 Citations2004Christine Mauck, Debra H. Weiner +4 more
Results suggest that 0.5% and 1.0% C31G are less irritating to the female genital tract than 1.7% C 31G or Extra Strength Gynol II.
ContraceptionMicrobicides—evaluating multiple formulations of C31G
47 Citations2002Richard Bax, Karen Douville +4 more
C31G, a surface active anti-infective agent that is active in vitro against bacterial and viral STD pathogens, was evaluated in a 3-day, once-daily dosing clinical trial designed to assess multiple formulations for safety and acceptance.
ContraceptionSafety of single daily use for one week of C31G HEC gel in women
41 Citations2002Susan A. Ballagh, Jay M. Baker +2 more
The C31G HEC product had a similar safety profile to N-9 in this comparative trial and product acceptability of C31g HEC was limited by the sensation of heat or burning.
American Journal of Obstetrics and GynecologySubgroup analysis in obstetrics clinical trials
41 Citations2007Mark A. Klebanoff
It is correct to determine whether treatment is effective among a subgroup of patients according to the probability value in that particular subgroup, but even when done correctly, most subgroup differences in treatment effectiveness prove to be spurious.
Sexually Transmitted DiseasesPregnancy in Effectiveness Trials of HIV Prevention Agents
33 Citations2007Elizabeth G. Raymond, Douglas Taylor +7 more
The basic design of HIV prevention trials is standard: HIV-negative women at risk for HIV infection are randomly assigned to use either the study product or a placebo according to a specified schedule and then are followed to assess HIV incidence.
ContraceptionA phase I comparative postcoital testing study of three concentrations of C31G
28 Citations2004Christine Mauck, Mitchell D. Creinin +6 more
All three concentrations of C31G are likely to give reasonable results in a contraceptive effectiveness trial, and the 1.0% concentration has been selected for further development, including Phase III trials of contraceptive effectiveness.
ContraceptionMale tolerance study of 1% C31G
21 Citations2004Christine Mauck, Ron G. Frezieres +4 more
Based on the observations in this study, C31G appears to be at least as safe and acceptable for male penile exposure as the marketed product ES Gynol II.